Original articlePrevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
Section snippets
Study design/patients
Consecutive patients with plaque psoriasis were enrolled at 34 dermatology centers in 7 European and North American countries (Belgium, Canada, Denmark, France, Germany, Hungary, and the United States) from August 2010 to July 2011. Eligible patients were aged at least 18 years and were initially assessed by a dermatologist for plaque psoriasis regardless of severity. Patients were subsequently evaluated by a rheumatologist, who completed a medical history and physical examination and made a
Patient disposition
Of the 1013 patients enrolled in this study (Table I), 959 had confirmed plaque psoriasis based on the initial dermatologist visit; 959 patients underwent the first rheumatologist assessment (based on medical history and physical examination) and 949 underwent the second rheumatologist assessment (based on medical history, physical examination, and laboratory tests). The following numbers of patients underwent imaging studies: radiographs of hand/wrists and feet/ankles, n = 188 (18.6%);
Discussion
In this large, multinational noninterventional prevalence study, the prevalence of PsA in patients with psoriasis was approximately 30%. Methodological differences among PsA prevalence studies mean that the comparison of findings is a precarious exercise. The 30% estimate reported here appears to be consistent with findings from at least 1 recent, similarly conducted study,16 and falls within the range established by others.15, 17, 18
Of the 285 patients given the diagnosis of PsA by a
References (21)
- et al.
Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis
Arthritis Rheum
(2001) - et al.
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey
Arch Dermatol
(2001) - et al.
Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health
J Rheumatol
(2010) - et al.
Work disability in psoriatic arthritis: a systematic review
Rheumatology (Oxford)
(2012) - et al.
Psoriatic arthritis: epidemiology, clinical features, course
outcome. Ann Rheum Dis
(2005) - et al.
Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis
J Rheumatol
(2001) - et al.
Mortality studies in psoriatic arthritis; results from a single outpatient clinic, I: causes and risk of death
Arthritis Rheum
(1997) - et al.
Mortality studies in psoriatic arthritis; results from a single outpatient center, II: prognostic indicators for death
Arthritis Rheum
(1998) - Chin YY, Yu HS, Li WC, Ko YC, Chen GS, Wu CS, et al. Arthritis as an important determinant for psoriatic patients to...
Psoriatic arthritis from Wright's era until today
J Rheumatol
(2009)
Cited by (382)
A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies
2024, Journal of the American Academy of DermatologyJanus kinase inhibitors for the treatment of psoriatic arthritis
2024, Indian Journal of Dermatology, Venereology and LeprologyNew analyses exploring multimorbidity in psoriasis
2024, British Journal of DermatologyChoosing Systemic Agents for Psoriasis
2024, Annals of PharmacotherapyThe economic burden of diseases in the Nordic countries: A systematic review
2024, Scandinavian Journal of Public Health
The PREPARE study was sponsored by Pfizer Inc. Editorial/medical writing support was provided by Donna McGuire of UBC Scientific Solutions and was funded by Pfizer Inc.
Disclosure: Dr Mease received grant support and/or honoraria for consultations or speaking engagements from Abbott, Amgen, Biogen Idec, Bristol Myers Squibb, Celgene, Crescendo, Forest, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer Inc, UCB, and Vertex. Dr Gladman received grant support from Abbot, Amgen, Bristol Myers Squibb, Janssen, Pfizer Inc, and UCB. Dr Khraishi received unrestricted educational grants from Pfizer Canada. Dr Thaçi received honoraria for consultations or speaking engagements from Abbott, Amgen, Astellas, Biogen Idec, Celgene, Janssen, Leo, Lilly, MSD, Novartis, and Pfizer Inc. Dr Behrens received grant support and/or honoraria for consultations or speaking engagements from Abbott, Biotest, Chugai, MorphoSys, Pfizer Inc, Roche, and UCB. Dr Northington is an employee of inVentiv Health, paid contractors to Pfizer Inc in providing statistical support for the PREPARE study and the development of this manuscript. Dr Boggs was an employee of Pfizer Inc at the time of study conduct and manuscript development. Ms Fuiman, Dr Bananis, and Dr Alvarez are current employees of Pfizer Inc and owners of Pfizer Inc stock. Dr Papp has no conflicts of interest to declare.